Cicero Kara I, Banerjee Rahul, Kwok Mary, Dima Danai, Portuguese Andrew J, Chen Delphine, Chalian Majid, Cowan Andrew J
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Division of Hematology and Oncology, School of Medicine, University of Washington, Seattle, WA 98115, USA.
Diagnostics (Basel). 2025 Jan 18;15(2):215. doi: 10.3390/diagnostics15020215.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT with [F]fluorodeoxyglucose (FDG) have improved sensitivity for the detection of myeloma bone disease compared to traditional skeletal surveys, and such advanced imaging also provides this field with better tools for detecting early signs of progression. Herein, we review the data supporting the use of advanced imaging for both diagnostics and prognostication in myeloma precursor conditions.
意义未明的单克隆丙种球蛋白病(MGUS)和冒烟型多发性骨髓瘤(SMM)是多发性骨髓瘤的无症状前驱疾病,影响着高达5%的40岁以上人群。骨受累作为骨髓瘤的定义性事件,是患者发病的主要来源。骨髓瘤前驱疾病管理的关键目标包括:(1)识别进展为伴有骨受累的多发性骨髓瘤风险最高的患者;(2)区分前驱状态与需要治疗的活动性骨髓瘤。与传统的骨骼检查相比,计算机断层扫描(CT)、磁共振成像(MRI)以及使用[F]氟脱氧葡萄糖(FDG)的正电子发射断层扫描(PET)-CT对骨髓瘤骨病的检测敏感性有所提高,这种先进的成像技术也为该领域提供了更好的工具来检测疾病进展的早期迹象。在此,我们综述支持在骨髓瘤前驱疾病的诊断和预后评估中使用先进成像技术的数据。